Axsome Therapeutics (AXSM) Research & Development (2022 - 2025)
Historic Research & Development for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $40.2 million.
- Axsome Therapeutics' Research & Development fell 1151.41% to $40.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.5 million, marking a year-over-year increase of 1634.39%. This contributed to the annual value of $187.1 million for FY2024, which is 9100.4% up from last year.
- Per Axsome Therapeutics' latest filing, its Research & Development stood at $40.2 million for Q3 2025, which was down 1151.41% from $49.5 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Research & Development ranged from a high of $55.0 million in Q4 2024 and a low of $12.6 million during Q1 2022
- Its 4-year average for Research & Development is $31.8 million, with a median of $30.8 million in 2023.
- As far as peak fluctuations go, Axsome Therapeutics' Research & Development surged by 14222.83% in 2024, and later plummeted by 1151.41% in 2025.
- Quarter analysis of 4 years shows Axsome Therapeutics' Research & Development stood at $14.7 million in 2022, then skyrocketed by 109.64% to $30.8 million in 2023, then soared by 78.57% to $55.0 million in 2024, then dropped by 26.99% to $40.2 million in 2025.
- Its Research & Development was $40.2 million in Q3 2025, compared to $49.5 million in Q2 2025 and $44.8 million in Q1 2025.